{"title":"将全身性 IL-2 靶向 BCMA CAR-T 细胞","authors":"Yuzhe Shi, Michel Sadelain","doi":"10.1038/s41590-024-01993-9","DOIUrl":null,"url":null,"abstract":"CAR-T cells are revolutionizing the treatment of cancer and other diseases. A latest iteration in development involves fusion with an antigen-based CAR enhancer to provide low-affinity IL-2 signaling that might limit adverse effects.","PeriodicalId":19032,"journal":{"name":"Nature Immunology","volume":null,"pages":null},"PeriodicalIF":27.7000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting systemic IL-2 to BCMA CAR-T cells\",\"authors\":\"Yuzhe Shi, Michel Sadelain\",\"doi\":\"10.1038/s41590-024-01993-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"CAR-T cells are revolutionizing the treatment of cancer and other diseases. A latest iteration in development involves fusion with an antigen-based CAR enhancer to provide low-affinity IL-2 signaling that might limit adverse effects.\",\"PeriodicalId\":19032,\"journal\":{\"name\":\"Nature Immunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":27.7000,\"publicationDate\":\"2024-10-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41590-024-01993-9\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41590-024-01993-9","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
CAR-T 细胞正在彻底改变癌症和其他疾病的治疗方法。最新的研发成果包括与基于抗原的 CAR 增强器融合,以提供低亲和性 IL-2 信号,从而限制不良反应。
CAR-T cells are revolutionizing the treatment of cancer and other diseases. A latest iteration in development involves fusion with an antigen-based CAR enhancer to provide low-affinity IL-2 signaling that might limit adverse effects.
期刊介绍:
Nature Immunology is a monthly journal that publishes the highest quality research in all areas of immunology. The editorial decisions are made by a team of full-time professional editors. The journal prioritizes work that provides translational and/or fundamental insight into the workings of the immune system. It covers a wide range of topics including innate immunity and inflammation, development, immune receptors, signaling and apoptosis, antigen presentation, gene regulation and recombination, cellular and systemic immunity, vaccines, immune tolerance, autoimmunity, tumor immunology, and microbial immunopathology. In addition to publishing significant original research, Nature Immunology also includes comments, News and Views, research highlights, matters arising from readers, and reviews of the literature. The journal serves as a major conduit of top-quality information for the immunology community.